Claris GenomiX Looks to Transform Precision Oncology Through Its Groundbreaking mRNA-Based Diagnostics
"At Claris GenomiX, we have made significant discoveries and major advances in computational cancer biology and methods for developing clinical-grade diagnostics," said Dr. Steven Buechler, co-founder and CSO.
- "At Claris GenomiX, we have made significant discoveries and major advances in computational cancer biology and methods for developing clinical-grade diagnostics," said Dr. Steven Buechler, co-founder and CSO.
- Precision oncology aspires to match a cancer patient with the drug or drugs that best treats the patient's particular tumor biology.
- Quantification of mRNA using today's technology has the potential to take precision oncology to the next level.
- Visit Claris GenomiX's website to learn more about ClarisInsight and to download a white paper on their precision oncology platform.